Allison Brashear

Allison Brashear can speak to the media about issues relating to medical education and health sciences education, diversity in medicine, including women’s leadership in the field, and health equity and community engagement on COVID-19 and other issues.

Brashear is an internationally recognized expert in Rapid Onset Dystonia Parkinsonism (RDP), and ATP1A3-related diseases and dystonia/spasticity clinical trials. Funded by the NIH since 2008, Brashear and her team have been experts on RDP, a genetic syndrome triggered by physiologic stress.   

She is an internationally renowned researcher whose work has fundamentally transformed the way spasticity and dystonia are treated. She led the first clinical trial to demonstrate that botulinum toxin can successfully treat wrist and finger spasticity in stroke victims. She was principal investigator on 40 clinical trials in cervical dystonia and spasticity, leading to 3 FDA-approved medications to treat patients with disabling muscle spasms.

Brashear holds an MBA from Duke University. She completed a public health leadership program for physicians as well as a yearlong national program for women leaders in academic medicine.

Allison Brashear, MD
Vice President for Health Sciences, University at Buffalo
Dean, Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo
Chair, UB Associates Board of Directors

•  Allison Brashear can be reached through Ellen Goldbaum in University Communications at 716-645-4605 or goldbaum@buffalo.edu
• Allison Brashear’s website